Luisa Bracci is Full Professor of Biochemistry at the University of Siena, where she leads the Biochemistry and Molecular Mechanisms of Cancer Research Group, within the Department of Medical Biotechnologies. A biologist by training with a PhD in Animal Biology, she began her scientific career at the Sclavo Research Center, studying peptide antigens and monoclonal antibodies. Over the years, her research has focused on the design and production of bioactive molecules, particularly peptides and antibody fragments, for diagnostic and therapeutic use. She has developed a strong interest in tumor-targeting peptides and in identifying novel cancer biomarkers, with a special focus on tumor microenvironment and proteoglycans. Since 2016, she has directed the U&E PreMed Laboratory, part of the University’s MedBiotech Hub, which provides advanced technological platforms for translational research. Professor Bracci has served twice as Director of the Department of Medical Biotechnologies and is currently a member of the Academic Senate. She also sits on the Scientific Committee of the Siena Biotecnopolo Foundation and coordinates the “Innovative Translational Medicine” spoke of the Tuscany Health Ecosystem. Author of several patents, she is also a co-founder of SetLance srl, a biotech company dedicated to developing peptide-based therapeutics. She is Member of the American Association for Cancer Research AACR